Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Galecto, Inc. (DMRA : NSDQ)

• Company Description    Damora Therapeutics Inc is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company is engaged in the advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms. Damora Therapeutics Inc., formerly known as Galecto Inc, is based in Denmark. Number of Employees: 7

• Price / Volume Information    Yesterday's Closing Price: $30.06 Daily Weekly Monthly 20 Day Moving Average: 293,519 shares Shares Outstanding: 61.74 (millions) Market Capitalization: $1,855.77 (millions) Beta: 1.46 52 Week High: $38.33 52 Week Low: $2.45 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.76% 2.22% 12 Week 49.78% 46.59% Year To Date 30.64% 15.86%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 221 Crescent Street Building 23 Suite 105 - WALTHAM,MA 02453 DNK ph: 781-281-9020 fax: - investors@damoratx.com http://www.damoratx.com

• General Corporate Information    Officers Carl Goldfischer - Chairman Sherwin Sattarzadeh - Chief Operating Officer Lori Firmani - Chief Financial Officer Julianne Bruno - Director Jayson Dallas - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G2646Y104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/05/26 Share - Related Items Shares Outstanding: 61.74 Most Recent Split Date: 8.00 (0.04:1) Beta: 1.46 Market Capitalization: $1,855.77 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.52 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.06 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.79 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 85.00% vs. Previous Quarter: 37.10% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - -176.39 03/31/26 - -428.30 12/31/25 - - ROA 06/30/26 - -77.86 03/31/26 - -114.62 12/31/25 - -279.49 Current Ratio 06/30/26 - 19.73 03/31/26 - 22.49 12/31/25 - 12.98 Quick Ratio 06/30/26 - 19.73 03/31/26 - 22.48 12/31/25 - 12.98 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - 6.27 03/31/26 - 6.29 12/31/25 - -110.11 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - - Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©